title: [Obesity and metabolic syndrome: clinical and therapeutic review].
abstract: The recent ATP III classification defines metabolic syndrome as including > or = 3 of the following characteristics: abdominal adiposity, atherogenic dyslipidemia, high blood pressure, and insulin resistance. In these patients the visceral fat may produce inflammatory cytokines that may account for an enhanced cardiovascular risk. The treatment of obese patients is complex and often ineffective: patients may initially reduce weight but subsequently regain or even increase it, according to the so-called "yo-yo syndrome". Given the difficulties of treatment of patients with increased BMI, visceral adiposity, or metabolic syndrome, a multidisciplinary approach to these patients may yield more frequent positive results. The different strategies that may be applied, in varying mix targeted to the individual patient, include diet, drugs, educational and psychological support and, in few selected cases, surgery.
authors.affiliation: Ambulatorio Obesità e Dislipidemie, Unità Operativa di Medicina Interna, Ospedale Bellaria, Bologna (I), Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Cuppini
authors.forename: Paola
authors.initials: P
authors.lastname: Matteini
mesh_terms: D001067:Appetite Depressants / Q000627:therapeutic use; D015992:Body Mass Index; D001835:Body Weight; D002318:Cardiovascular Diseases / Q000209:etiology; D003503:Cyclobutanes / Q000627:therapeutic use; D015444:Exercise; D006801:Humans; D024821:Metabolic Syndrome / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D009765:Obesity / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D010353:Patient Education as Topic; D011613:Psychotherapy
chemical_list: D001067:Appetite Depressants; D003503:Cyclobutanes; C058254:sibutramine